Key Takeaways ADMA reported Q4 revenues of $139.2M, up 18%, with adjusted EPS rising to 21 cents.Asceniv sales jumped 51% in 2025 to $363M, fueling total revenue growth of 20%.ADMA guides 2026 revenues above $635M as yield-enhanced output boosts margins.ADMA Biologics (ADMA) reported fourth-quarter 2025 adjusted earnings per share (EPS) of 21 cents, (excluding stock-based compensation modifications, yield enhancement expense up, voluntary withdrawal and product replacements and non-recurring professional fe ...

ADMA Biologics (NasdaqGM:ADMA) Q4 2025 Earnings call February 25, 2026 04:30 PM ET Company ParticipantsAdam Grossman - President and CEOAnthony Petrone - MD and Equity ResearchBrad Tade - CFO and TreasurerKaitlin Kestenbaum - COO and SVP ComplianceRick Miller - MDTerry-Ann Kohler - CFO and TreasurerNone - Company RepresentativeOperatorGood afternoon. Welcome to the ADMA Biologics full year 2025 financial results and business update conference call on Wednesday, February 25, 2026. At this time, all participa ...

ADMA Biologics (NasdaqGM:ADMA) Q4 2025 Earnings call February 25, 2026 04:30 PM ET Company ParticipantsAdam Grossman - President and CEOAnthony Petrone - MD and Equity ResearchBrad Tade - CFO and TreasurerKaitlin Kestenbaum - COO and SVP ComplianceRick Miller - MDTerry-Ann Kohler - CFO and TreasurerNone - Company RepresentativeOperatorGood afternoon. Welcome to the ADMA Biologics full year 2025 financial results and business update conference call on Wednesday, February 25, 2026. At this time, all participa ...

ADMA Biologics (NasdaqGM:ADMA) Q4 2025 Earnings call February 25, 2026 04:30 PM ET Speaker4Good afternoon. Welcome to the ADMA Biologics full year 2025 financial results and business update conference call on Wednesday, February 25, 2026. At this time, all participants are in a listen-only mode. There will be a question and answer session to follow. Please be advised that this call is being recorded at the company's request and will be available on the company's website approximately two hours following the ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36728 ADMA BIOLOGICS, INC. (Exact Name of Registrant as Specified in Its Charter) | Delaware | 56-2590442 | | --- | --- | | (State or Other J ...

FY 2025 Total Revenue of $510 Million, Representing 20% Year-Over-Year Growth FY 2025 ASCENIV Revenue Grew to $363 Million, Representing 51% Year-Over-Year Growth FY 2025 Adjusted Net Income(1) of $161 Million, Representing 35% Year-Over-Year Growth FY 2025 Adjusted EBITDA(2) of $231 Million, Representing 40% Year-Over-Year Growth Incoming CFO Appointment Expected to Further Enhance Financial Strategy, Working Capital Execution and Capital Allocation Discipline Advancing SG-001 Pipeline Program with Anticip ...

Core Viewpoint - ADMA Biologics, Inc. will report its fourth quarter and full year 2025 financial results on February 25, 2026, followed by a conference call to discuss these results and company updates [1]. Group 1: Company Overview - ADMA Biologics is a U.S.-based biopharmaceutical company focused on manufacturing, marketing, and developing specialty biologics for immunodeficient patients and those at risk for infectious diseases [3]. - The company currently offers three FDA-approved plasma-derived biologics: ASCENIV™, BIVIGAM, and NABI-HB, aimed at treating immune deficiencies and preventing certain infectious diseases [3]. - ADMA is also developing SG-001, a pre-clinical hyperimmune globulin targeting S. pneumonia [3]. - The company operates an FDA-licensed plasma fractionation and purification facility in Boca Raton, Florida, and has a subsidiary, ADMA BioCenters, which collects source plasma for its products [3]. - ADMA holds numerous U.S. and foreign patents related to its products and candidates [3].

Core Insights - ADMA Biologics' shares have increased by 13.8% over the past three months, outperforming the industry growth of 9% and the S&P 500 [1][8] - The stock's recovery is attributed to strong demand for its product Asceniv and a positive outlook for 2026 [4][19] Company Performance - ADMA Biologics specializes in plasma-derived biologics aimed at treating immune deficiencies and preventing certain infectious diseases [5][6] - The company's revenue is driven by three FDA-approved products: Bivigam, Asceniv, and Nabi-HB [5] - Asceniv, the lead product, is a plasma-derived IVIG that contains polyclonal antibodies to combat infections [6][7] Growth Drivers - Utilization of Asceniv has accelerated due to increased prescriber adoption, payer access, and confidence in product availability [8][9] - ADMA divested three plasma collection centers for $12 million and entered long-term plasma supply agreements, enhancing its sourcing model [9][10] - The company has successfully implemented yield-enhanced production, which is expected to improve gross margins starting in 2026 [10][11] Financial Outlook - ADMA raised its 2026 revenue forecast to approximately $635 million from $630 million, with adjusted EBITDA guidance increased to about $360 million [13] - Management projects revenues of approximately $775 million in 2027 and over $1.1 billion by fiscal 2029 [14] - The company's shares currently trade at a price/sales ratio of 7.96x, significantly higher than the industry average of 2.07x [15] Market Position - ADMA competes with Takeda and Grifols in the U.S. plasma-derived products market and is well-positioned for growth due to increasing demand for Asceniv [19]

Core Viewpoint - ADMA Biologics has been a favored stock for a significant period, with extensive coverage provided on Seeking Alpha, indicating strong interest and potential in the company [1]. Company Summary - ADMA Biologics has been the subject of nine articles written between 2021 and 2022, showcasing a consistent focus on the company's performance and prospects [1]. - The company is associated with a corporate lawyer, Jeffrey Himelson, who has a background in hedge funds and has gained recognition for his investment insights [1]. Analyst's Position - The analyst holds a beneficial long position in ADMA shares, indicating confidence in the company's future performance [2].

Core Viewpoint - ADMA Biologics has been a favored stock for a significant period, with extensive coverage provided on the company, indicating strong interest and potential in its performance [1]. Group 1 - The company has been the subject of nine articles published on Seeking Alpha between 2021 and 2022, showcasing a consistent analysis and interest in its stock [1]. - The author of the articles has a beneficial long position in ADMA shares, indicating confidence in the company's future performance [2]. - The author is not receiving compensation for the articles, suggesting an independent analysis of the company's prospects [2].